European Medicines Agency reminds physicians to use Tecentriq (atezolizumab) with nab-paclitaxel, not conventional paclitaxel, when treating breast cancer

This advice follows the release of data from the Impassion131 study, which found atezolizumab in combination with conventional paclitaxel did not slow down disease progression or reduce deaths in patents with inoperable locally advanced or metastatic triple-negative breast cancer

Source:

European Medicines Agency